Drugs /

peg-proline-interferon alfa-2b

Back to Drugs List

Overview

NCI Definition [1]:
A long-acting formulation of recombinant interferon alpha subtype 2b (IFN-a2b) protein, in which IFN-a2b is coupled, via proline, to polyethylene glycol (PEG), with antiviral, immunomodulating and antineoplastic activities. Upon subcutaneous administration, IFN-a2b binds to specific interferon cell-surface receptors. This activates interferon-mediated signal transduction pathways and induces the transcription and translation of genes with interferon-specific response elements (ISREs); the protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety inhibits proteolytic breakdown and clearance of IFN-a2b, which prolongs its half-life, extends the duration of its therapeutic effects and allows less frequent dosing. The proline linker facilitates the synthesis of a predominant (90%) positional isomer which allows for further increases in stability and a longer half-life than previous PEG conjugates.

Clinical Trials

View Clinical Trials for peg-proline-interferon alfa-2b

Peg-proline-interferon alfa-2b has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating peg-proline-interferon alfa-2b, 1 is phase 2 (1 open).

BCR-ABL1 Fusion and t(9;22)(q34;q11) are the most frequent biomarker inclusion criteria for peg-proline-interferon alfa-2b clinical trials.

Chronic myeloid leukemia is the most common disease being investigated in peg-proline-interferon alfa-2b clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Peg-Proline-Interferon Alfa-2b
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating peg-proline-interferon alfa-2b and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
peg intron, peg-proline-infalpha-2b, peg-p-ifn-alfa-2b, p1101, peg-p-ifn-alpha-2b, peg-p-ifn-alfa-2b, pegylated interferon alpha-2b, aop2014, peg-proline-interferon alpha-2b, peg interferon alpha-2b, peg-p-ifn-alpha-2b, pegylated interferon alfa-2b, peg-proline-interferon alpha-2b
Drug Target(s) [2]:
IFNAR1, IFNAR2
NCIT ID [1]:
C111892

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.